Standard

Anti‐idiotypic agonistic antibodies : Candidates for the role of universal remedy. / Stanova, Aliya K.; Ryabkova, Varvara A.; Tillib, Sergei V.; Utekhin, Vladimir J.; Churilov, Leonid P.; Shoenfeld, Yehuda.

в: Antibodies (Basel, Switzerland), Том 9, № 2, 19, 06.2020.

Результаты исследований: Научные публикации в периодических изданияхОбзорная статьяРецензирование

Harvard

APA

Vancouver

Author

BibTeX

@article{e9f5af35c3f749e1b8f91297933e6976,
title = "Anti‐idiotypic agonistic antibodies: Candidates for the role of universal remedy",
abstract = "Anti‐idiotypic antibodies (anti‐IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti‐IDs: α, β, γ, ε, and δ. Due to the ability of internal‐image anti‐IDs to compete with an antigen for binding to antibody and to alter the biologic activity of an antigen, anti‐IDs have become a target in the search for new treatments of autoimmune illnesses, cancer, and some other diseases. In this review, we summarize the data about anti‐IDs that mimic the structural and functional properties of some bioregulators (autacoids, neurotransmitters, hormones, xenobiotics, and drugs) and evaluate their possible medical applications. The immune system is potentially able to reproduce or at least alter the effects of any biologically active endogenous or exogenous immunogenic agent via the anti‐idiotypic principle, and probably regulates a broad spectrum of cell functions in the body, being a kind of universal remedy or immunacea, by analogy to the legendary ancient goddess of universal healing Panacea (Πανάκεια, Panakeia in Greek) in the treatment and prevention of diseases, possibly including non‐infectious somatic and even hereditary ones.",
keywords = "Agonistic autoantibodies, Anti‐idiotypic antibodies, Autacoid, Drug, Hormone, Neurotransmitter",
author = "Stanova, {Aliya K.} and Ryabkova, {Varvara A.} and Tillib, {Sergei V.} and Utekhin, {Vladimir J.} and Churilov, {Leonid P.} and Yehuda Shoenfeld",
note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = jun,
doi = "10.3390/antib9020019",
language = "English",
volume = "9",
journal = "Antibodies",
issn = "2073-4468",
publisher = "MDPI AG",
number = "2",

}

RIS

TY - JOUR

T1 - Anti‐idiotypic agonistic antibodies

T2 - Candidates for the role of universal remedy

AU - Stanova, Aliya K.

AU - Ryabkova, Varvara A.

AU - Tillib, Sergei V.

AU - Utekhin, Vladimir J.

AU - Churilov, Leonid P.

AU - Shoenfeld, Yehuda

N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/6

Y1 - 2020/6

N2 - Anti‐idiotypic antibodies (anti‐IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti‐IDs: α, β, γ, ε, and δ. Due to the ability of internal‐image anti‐IDs to compete with an antigen for binding to antibody and to alter the biologic activity of an antigen, anti‐IDs have become a target in the search for new treatments of autoimmune illnesses, cancer, and some other diseases. In this review, we summarize the data about anti‐IDs that mimic the structural and functional properties of some bioregulators (autacoids, neurotransmitters, hormones, xenobiotics, and drugs) and evaluate their possible medical applications. The immune system is potentially able to reproduce or at least alter the effects of any biologically active endogenous or exogenous immunogenic agent via the anti‐idiotypic principle, and probably regulates a broad spectrum of cell functions in the body, being a kind of universal remedy or immunacea, by analogy to the legendary ancient goddess of universal healing Panacea (Πανάκεια, Panakeia in Greek) in the treatment and prevention of diseases, possibly including non‐infectious somatic and even hereditary ones.

AB - Anti‐idiotypic antibodies (anti‐IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti‐IDs: α, β, γ, ε, and δ. Due to the ability of internal‐image anti‐IDs to compete with an antigen for binding to antibody and to alter the biologic activity of an antigen, anti‐IDs have become a target in the search for new treatments of autoimmune illnesses, cancer, and some other diseases. In this review, we summarize the data about anti‐IDs that mimic the structural and functional properties of some bioregulators (autacoids, neurotransmitters, hormones, xenobiotics, and drugs) and evaluate their possible medical applications. The immune system is potentially able to reproduce or at least alter the effects of any biologically active endogenous or exogenous immunogenic agent via the anti‐idiotypic principle, and probably regulates a broad spectrum of cell functions in the body, being a kind of universal remedy or immunacea, by analogy to the legendary ancient goddess of universal healing Panacea (Πανάκεια, Panakeia in Greek) in the treatment and prevention of diseases, possibly including non‐infectious somatic and even hereditary ones.

KW - Agonistic autoantibodies

KW - Anti‐idiotypic antibodies

KW - Autacoid

KW - Drug

KW - Hormone

KW - Neurotransmitter

UR - http://www.scopus.com/inward/record.url?scp=85089125922&partnerID=8YFLogxK

U2 - 10.3390/antib9020019

DO - 10.3390/antib9020019

M3 - Review article

C2 - 32481667

VL - 9

JO - Antibodies

JF - Antibodies

SN - 2073-4468

IS - 2

M1 - 19

ER -

ID: 53803984